Claim · 2024-11-20 · announcement · Stated in source · Supported

Recursion stated on 20 November 2024 that its business combination with Exscientia had been completed, with Exscientia becoming a wholly owned subsidiary of Recursion.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Recursion Pharmaceuticals → acquired → Exscientia

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Recursion Pharmaceuticalsacquired ↓Exscientia

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2024-11-20 · announcement Records dated 2024 →

Scope and limitsRecursion's statement of completion, filed as an exhibit to its Form 8-K; the record does not state the consideration paid at closing or the legal steps (the 2024-08-08 announcement describes a court-sanctioned scheme).

The evidence 01

primary sourceSupports the claim

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion Pharmaceuticals, Inc. (Exhibit 99.3 to Form 8-K) · 2024-11-20

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion”

Location in source first paragraph

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Recursion Pharmaceuticals, Inc. (Exhibit 99.3 to Form 8-K)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 6021636642d52396295faf64b9940ddb7a277d4571865c4aa767274c26498245). Exhibit 99.3 to Form 8-K filed 2024-11-20, accession 0001601830-24-000217, as served by SEC EDGAR on 2026-10-30. Its wording can change; earlier wording is not authenticated.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Recursion Pharmaceuticals, Inc. (Exhibit 99.3 to Form 8-K), “Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery”, 2024-11-20.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (28 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A23) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An acquisition of the named organisation, with timing and scope qualified by the evidence. Distinct from an internal reorganisation or team combination.

Date. Date of Recursion's press release reporting completion. The Form 8-K to which the release is Exhibit 99.3 (accession 0001601830-24-000217, filed 2024-11-20) gives 2024-11-19 as its period of report (date of earliest event reported), under Item 2.01 Completion of Acquisition or Disposition of Assets, as its EDGAR filing index page shows (retrieved 2026-10-30); completion may therefore have taken effect on 19 November 2024. The 8-K body was not retrieved (HTTP 403).

Record ID aib-co-recursion-acquired-exscientia-2024